Egypt's healthcare sector is in the middle of its most ambitious transformation in decades. With a pharmaceutical market valued at $5 billion, health spending that has grown tenfold in a decade, and the largest drug manufacturing base in the Middle East and North Africa, the country is positioning itself as a regional healthcare powerhouse — not just a large market, but an increasingly self-sufficient one.
For pharma, medtech, and healthcare investors watching the MENA region, Egypt in 2026 demands attention. Here's why.
A Market in Rapid Expansion
Egypt's pharmaceutical market reached EGP 307 billion in 2024, a striking 42% year-on-year increase in revenue. The market is growing at three times the regional average, making it the second-largest pharma market in the Middle East and Africa by value (behind Saudi Arabia) and the largest by volume.
The broader healthcare market — including medical devices at $4 billion — is driven by rising chronic disease prevalence, a young and growing population of over 100 million, and increasing government expenditure. Hospital supplies lead the devices segment, followed by cardiovascular and orthopedic devices. Key international players including Pfizer, Novartis, GSK, Sanofi, Abbott, and Philips all maintain significant operations in the country.
Growth is projected at a CAGR of over 7% through 2027, with generics dominating due to favorable pricing policies and a population that relies heavily on out-of-pocket spending.
Pharma Manufacturing: MENA's Largest Base
Egypt operates the largest pharmaceutical manufacturing base in MENA, representing nearly 30% of the regional market. Local companies already meet 91% of domestic demand, with approximately 70% of production consisting of generic medicines.
In 2025, Egyptian pharma companies are adding 20 new production lines through EGP 4 billion ($80 million) in investments aimed at increasing capacity and reducing the country's $3 billion in annual pharmaceutical imports. The government's localization strategy is now targeting higher-value segments: oncology drugs, immunodeficiency treatments, radioactive dyes, and infant formula — categories historically dependent on imports.
The Egyptian Drug Authority (EDA) is positioning Egypt as a regional pharmaceutical production and distribution hub aligned with Egypt Vision 2030. A 2023 regulation mandating Good Manufacturing Practices (GMP) compliance for all manufacturers is raising quality standards to international benchmarks, a prerequisite for expanding exports — which reached $447 million in 2024.
Localizing pharmaceutical raw materials alone could save the country approximately $1 billion annually, though the challenge remains significant: nearly all active pharmaceutical ingredients (APIs) are still imported, with 75% of pharma imports being raw materials for domestic producers.
Universal Health Insurance: The 100-Million Goal
Egypt's Universal Health Insurance System (UHIS), launched in 2018, aims to provide equitable healthcare access and financial protection to the country's entire population. In early 2026, the Universal Health Insurance Authority (UHIA) held its 100th board meeting, approving critical governance measures:
- The first Anti-Abuse, Anti-Fraud, and Anti-Manipulation Policy to safeguard financial resources
- A 2026 Internal Audit and Governance Plan focused on transparency and risk management
- Renewed cooperation with the Ministry of Finance and a new agreement with WHO Egypt for capacity building
- A contract with Vodafone for hosting the authority's data center infrastructure through mid-2026
The system is currently operational in six governorates, covering approximately 6 million residents. Parallel to UHI, the Hayah Karima ("Decent Life") presidential initiative has allocated EGP 25 billion for its second phase in FY 2025/2026, targeting 1,667 villages across 20 governorates and reaching approximately 21 million citizens — with 29% of villages in Upper Egypt, the country's most underserved region.
The road to covering 100 million Egyptians remains long, but the institutional infrastructure and governance frameworks are maturing.
Digital Health Strategy 2025–2029
Egypt has unveiled a comprehensive 2025–2029 Digital Health Strategy as part of its broader Vision 2030 plan. The strategy signals a systemic shift toward digital-first healthcare delivery, encompassing AI-powered diagnostics, mobile health platforms, electronic health records, and wearable device integration.
Private sector investment is following the government's lead. WHM is considering a $1.8 billion investment in Egypt's healthcare sector, one of the largest single private commitments the market has seen. Growing digital health adoption, combined with Egypt's large, young, mobile-connected population, creates a compelling foundation for health tech scale-up.
Medical tourism is also expanding, driven by favorable weather, proximity to Europe, and treatment costs that are a fraction of those in the GCC — a trend that digital health infrastructure will only accelerate by enabling seamless pre- and post-treatment engagement.
Infrastructure: Building at Scale
Egypt has allocated EGP 406 billion to the health sector in 2025 — a tenfold increase from EGP 34 billion in 2013. Between 2014 and 2024, the Ministry of Health completed 1,245 infrastructure projects, with 20 more expected in 2025.
The current footprint includes approximately 2,000 hospitals, 5,400 primary healthcare units, and over 142,000 hospital beds (including 16,300 ICU beds), with plans to add 2,650 additional beds. Specialized medical cities are planned across 11 governorates, designed to reduce the burden on Cairo-centric facilities and bring advanced care closer to underserved populations.
Presidential health initiatives targeting Hepatitis C, chronic kidney disease, women's health, and cardiovascular disease have demonstrated that large-scale, nationally coordinated programs can deliver measurable outcomes — Egypt's Hepatitis C elimination campaign is widely cited as a global success story.
Challenges Ahead
Despite the momentum, several structural challenges persist:
- API import dependency: Nearly all active pharmaceutical ingredients are imported, making the supply chain vulnerable to currency fluctuations and global disruptions.
- Healthcare workforce gaps: Scaling infrastructure requires proportional growth in physicians, nurses, and specialists — a constraint Egypt shares with the broader region.
- Health expenditure per capita: Despite budget increases, per-capita health spending remains below global averages, and out-of-pocket costs still dominate for most citizens.
- UHI coverage pace: With six governorates covered out of 27, reaching full universal coverage will require sustained political will and financing over the next decade.
- Regulatory capacity: As the EDA pushes for international standards, building regulatory capacity to match the pace of market growth and manufacturing expansion remains critical.
What This Means for Patients and Industry
For patients, Egypt's healthcare trajectory is promising. Universal insurance expansion, infrastructure investment, and local drug manufacturing are converging to improve access and affordability — particularly for the 21 million citizens in underserved villages targeted by Hayah Karima.
For pharma and medtech, Egypt offers a rare combination: the largest manufacturing base in MENA, a $5 billion market growing at 7%+, and a government actively incentivizing localization in high-value therapeutic areas like oncology. Companies should evaluate local manufacturing partnerships, EDA registration pathways, and the expanding reimbursement landscape under UHI.
For investors, the $1.8 billion WHM consideration signals that sophisticated capital sees long-term value in Egyptian healthcare. Digital health, diagnostics, and hospital infrastructure represent the most immediate opportunities, with pharma manufacturing and medical tourism as structural tailwinds.
Egypt's healthcare market has moved past the question of potential. The infrastructure is being built, the policies are being enacted, and the capital is flowing. The question for 2026 is execution — and early movers will have a decisive advantage.